AngioDynamics(ANGO) - 2021 Q2 - Earnings Call Presentation

Financial Performance - AngioDynamics' Q2 FY2021 revenue increased by 40% year-over-year, reaching $72770 thousand compared to $70003 thousand in Q2 FY2020[8] - Gross margin for Q2 FY2021 was 552%, a decrease of 410 basis points compared to 593% in Q2 FY2020[8, 12] - Adjusted EPS for Q2 FY2021 was $001, a decrease of $005 from $006 in Q2 FY2020[8] - Adjusted EBITDA for Q2 FY2021 was $5158 thousand, a decrease of $1252 thousand from $6410 thousand in Q2 FY2020[8] - Free cash flow for Q2 FY2021 was $10087 thousand, an increase of $6773 thousand from $3314 thousand in Q2 FY2020[8] - AngioDynamics reaffirms FY2021 revenue guidance of $278 million to $284 million[7] Product Line Performance - NanoKnife disposable growth was 76% in the US and 30% worldwide[6] - AngioVac experienced growth of 24%[6, 9] - Vascular Access Midlines grew 17% in Q2 FY2021 and 53% year-to-date[10] - NanoKnife Capital experienced a decline of 50% in Q2 FY2021[11] Thrombus Management Portfolio - AngioDynamics is progressing toward the planned launch of a multi-purpose mechanical aspiration thrombectomy device in calendar 2021[6, 20] - AngioVac's use is currently focused on the Right Heart, which is a $77 million addressable market[20]